Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Randomized, Double-masked, Controlled, Parallel Group, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

NCT02623738 is registered in ClinicalTrials.gov with Santen Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02623738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02623738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Randomized, Double-masked, Controlled, Parallel Group, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-
Lead sponsor
Santen Pharmaceutical Co., Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
December 6, 2015
Completion date
February 10, 2017
Enrollment
253 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, primary open angle glaucoma